Skip to main content

Cinvanti News

FDA Approves Supplemental New Drug Application to Expand Cinvanti (aprepitant) Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC)

SAN DIEGO, Oct. 22, 2019 /PRNewswire/ – Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class...

FDA Approves Supplemental New Drug Application to Expand Cinvanti (aprepitant) Label for IV Push

SAN DIEGO, Feb. 26, 2019 /PRNewswire/ – Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class...

FDA Approves Cinvanti (aprepitant) Injectable Emulsion for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting (CINV)

SAN DIEGO--(BUSINESS WIRE)--Nov. 9, 2017-- Heron Therapeutics, Inc. (Nasdaq: HRTX) (the Company or Heron), a commercial-stage biotechnology company focused on developing novel, best-in-class...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Nausea / Vomiting, Nausea / Vomiting - Chemotherapy Induced

Cinvanti patient information at Drugs.com